Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
about
Mechanism of action of lenalidomide in hematological malignanciesBiological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaAre we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaRole of the tumor microenvironment in mature B-cell lymphoid malignanciesThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Plasmablastic Lymphoma: A Review of Current Knowledge and Future DirectionsLymphoma Immunotherapy: Current StatusConstitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell LymphomaImpaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryLenalidomide for the treatment of B-cell lymphoma.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacyThe clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersActivity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesL-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K AxisExpression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant diseaseLenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma.Thalidomide-a notorious sedative to a wonder anticancer drug.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
P2860
Q21198872-93A7B8FA-3C97-49D8-8A1F-40A5362BFFF3Q21285161-072171D8-751B-4772-8FCF-73F52B67BAD5Q24597424-8AF01935-EC77-44F0-8BC2-AE5EB7ED4DAAQ24607479-7C8506B3-F21C-426E-9DF2-876AE7A600FFQ26748775-49C83DCE-B037-4E85-AFFA-B80D3A180D8CQ26772907-4342953B-0AA5-41B8-B7BF-AABCB52B0487Q26781831-2706F9DE-3B23-4F6E-AB34-1694A4077A7CQ26782902-00272F70-078A-4CE9-9A3F-26E7E6C04393Q26853170-F0CE66D0-4E83-4DF4-B1BC-1C96A3133BC2Q27003955-0CEBFD93-31B5-4690-BDB4-3909E14AC892Q28088365-EBFE2AE6-EC50-4E98-8FA0-CFDC69593194Q30249007-78B82645-D206-4ADE-99C2-2A8CD5C546A4Q30358639-CCE5C1BE-6D56-4F06-8386-D41CA11CC9ECQ30659342-2F77A9EB-C30F-484B-BF0B-CC3A8C1884B9Q33387037-5E47EEDA-DD46-4088-9C1E-AFAD9E9BA7CFQ33388648-0D8BB1F1-570F-4AB4-93C1-EC936AF7B0CEQ33393623-9CFD4C54-F86A-40C7-93CC-AB7641983AC8Q33396036-90747DD1-67D6-4A0F-B2FE-E4C81BCE2052Q33397302-CD8306F8-B152-4911-9350-D55AF0D145D5Q33398019-C2D5E335-7ACE-4952-92EE-399593339091Q33398415-E838D1AB-08D2-4116-A0C7-955AD2699C14Q33406742-16CD483B-51B7-477C-AB34-3315F2989376Q33407102-36D1C10C-B5DE-4DFE-A630-7FC73F1B97B9Q33408772-D403673D-1979-4721-8146-1167E53FBDA9Q33410282-6A5889C3-8135-4AC1-89AB-B6F7BD51EF02Q33413210-F7AA2D32-99ED-42F3-90E3-5D0D4DA9C5AEQ33416550-DC88E34A-F418-4C12-BB82-46D49B1C797DQ33418964-A27BE1B9-AD80-424A-8150-B02EEAC85FA6Q33423873-1EC05125-C644-4617-9EDF-8A2568B790A2Q33439291-C07355AD-6B0D-45CD-AAD4-A091B561B532Q33685903-6B0FBDA1-143D-46AA-8C1C-1B8DDAD784B2Q33817800-E2BD6606-9713-498C-8FA5-2E86F8001532Q33832087-3A41F6D1-A0CC-4930-895E-A6BEF7887778Q33874179-BCD406AE-E9C9-494A-AC11-35E968D7F48DQ33911781-67EEABD1-5DD8-4ECB-A8FF-3D5FA2997F5BQ33946396-7B94929B-44E4-4CB3-B79B-A23D378857DBQ33956871-4F679FC8-BAA2-451C-860B-8872F86FC804Q34173071-EF96FD54-8096-4786-9CCA-DD1FB9F81D88Q34220013-F7C59744-33A7-42AE-91F6-FEA676824AF7Q34253548-7B6CE145-CAD0-4EF8-BBD6-947D5AAACAB3
P2860
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@ast
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
type
label
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@ast
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
prefLabel
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@ast
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
P2093
P356
P1476
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
@en
P2093
Annette Ervin-Haynes
Craig E Cole
Dennis Pietronigro
Glen Justice
Izidore S Lossos
Jerome B Zeldis
Joseph M Tuscano
Kenichi Takeshita
Kenton Wride
Kyle McBride
P304
P356
10.1200/JCO.2007.15.3429
P407
P50
P577
2008-07-07T00:00:00Z